von Willebrand's Disease Blog

Octapharma USA Announces FDA Approval of Wilate - the First Replacement Therapy Developed Specifically for von Willebrand Disease

Posted 9 Dec 2009 by Drugs.com

HOBOKEN, N.J., Dec. 7 /PRNewswire/ – Octapharma USA today announced the U.S. Food and Drug Administration has approved wilate for the treatment of spontaneous and trauma-induced bleeding episodes in patients with all types of von Willebrand disease (VWD). Wilate is a newly developed, high-purity, double virus inactivated von Willebrand Factor/Coagulation Factor VIII Concentrate (Human) that demonstrated efficacy for all types of VWD, including pediatric patients, in four prospective clinical trials utilizing both objective and subjective criteria. Wilate is indicated for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe VWD as well as patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated.(1) Wilate is the first double virus inactivated VWF/FVIII (von Willebrand Factor / ... Read more

Related support groups: von Willebrand's Disease